The trends in venous thromboembolism occurrence and prevention after minimally invasive varicose vein surgery
OBJECTIVES: To assess the trends of VTE occurrence and prevention in varicose vein surgery.
METHOD: The registry-based CAPSIVS trial (NCT03041805) analysis includes results in 1878 lower limbs. The primary outcome is a 28-day symptomatic or asymptomatic DVT revealed with duplex ultrasound.
RESULTS: Any DVT, including EHIT, was observed in 3.4%, while symptomatic in 0.5%. Prophylactic anticoagulation was administrated in 20.4% with LMWH (13.2%) or DOAC (7.1%) for patients with higher VTE risk but did not reduce the events rate. With propensity score matching DOACs were superior to LMWHs (1.5% vs 9.8%). Duration of anticoagulation was essential: the lowest incidence (4.2%) was associated with prophylaxis for up to 7 days, while a single LMWH injection resulted in a DVT rate of 8.8%. With individual VTE history, any anticoagulation duration appeared insufficient.
CONCLUSIONS: Prophylactic anticoagulation after varicose vein surgery should be based on the individual VTE risk and provided for ≥7-30 days.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Phlebology - 39(2024), 3 vom: 14. März, Seite 183-193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lobastov, Kirill [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/02683555231217364 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364739096 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364739096 | ||
| 003 | DE-627 | ||
| 005 | 20240314234652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/02683555231217364 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM364739096 | ||
| 035 | |a (NLM)37982381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lobastov, Kirill |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The trends in venous thromboembolism occurrence and prevention after minimally invasive varicose vein surgery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To assess the trends of VTE occurrence and prevention in varicose vein surgery | ||
| 520 | |a METHOD: The registry-based CAPSIVS trial (NCT03041805) analysis includes results in 1878 lower limbs. The primary outcome is a 28-day symptomatic or asymptomatic DVT revealed with duplex ultrasound | ||
| 520 | |a RESULTS: Any DVT, including EHIT, was observed in 3.4%, while symptomatic in 0.5%. Prophylactic anticoagulation was administrated in 20.4% with LMWH (13.2%) or DOAC (7.1%) for patients with higher VTE risk but did not reduce the events rate. With propensity score matching DOACs were superior to LMWHs (1.5% vs 9.8%). Duration of anticoagulation was essential: the lowest incidence (4.2%) was associated with prophylaxis for up to 7 days, while a single LMWH injection resulted in a DVT rate of 8.8%. With individual VTE history, any anticoagulation duration appeared insufficient | ||
| 520 | |a CONCLUSIONS: Prophylactic anticoagulation after varicose vein surgery should be based on the individual VTE risk and provided for ≥7-30 days | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Varicose veins surgery | |
| 650 | 4 | |a anticogulation | |
| 650 | 4 | |a caprini risk score | |
| 650 | 4 | |a prophylaxis | |
| 650 | 4 | |a venous thromboembolism | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Shaldina, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Matveeva, Athena |e verfasserin |4 aut | |
| 700 | 1 | |a Kovalchuk, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Borsuk, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Schastlivtsev, Ilya |e verfasserin |4 aut | |
| 700 | 1 | |a Laberko, Leonid |e verfasserin |4 aut | |
| 700 | 1 | |a Fokin, Alexey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phlebology |d 1996 |g 39(2024), 3 vom: 14. März, Seite 183-193 |w (DE-627)NLM089782844 |x 1758-1125 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:3 |g day:14 |g month:03 |g pages:183-193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/02683555231217364 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 3 |b 14 |c 03 |h 183-193 | ||